Roche's Kadcyla (trastuzumab emtansine) Receives Health Canada's Approval for The Treatment of HER2-Positive Early Breast Cancer After Surgery
Shots:
- The approval is based on P-III KATHERINE study assessing Kadcyla vs Herceptin as adjuvant therapy in people with HER2+ eBC with pathological residual invasive disease in the breast and/or axillary lymph nodes following neoadjuvant taxane and Herceptin-based treatment
- The P-III KATHERINE study results: reduction in the risk of residual invasive BC recurrence or death from any cause; @3yrs. reoccurrence of BC (88.3% vs 77%); patients with the residual invasive disease after neoadjuvant treatment have a worse prognosis than those with no detectable disease
- Kadcyla (trastuzumab emtansine) is an ADC- a combination of trastuzumab and DM1- delivering CT directly to HER2+ cancer cells. It has received approval in 104 countries including the US & EU for HER2+ m-breast cancer and is developed using ADC technology licensed from ImmunoGen
Click here to read full press release/ article
Ref: Newswire Canada | Image: Roche
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].
